Clairity has received U.S. FDA De Novo authorization for CLAIRITY BREAST, a prognostic platform designed to predict five-year breast cancer risk.
Clairity Becomes the First FDA-Authorized AI Platform for Breast Cancer Prediction – Historic Milestone for Women’s Health
